Explore how strategic intelligence agencies and competitive intelligence solutions are shaping the pharmaceutical industry. Download our guide to technological advancements and more invaluable ...
The Phase III KOASTAL-1 study with Neumora’s lead asset navacaprant failed to meet its primary and secondary endpoint.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback